A 19-year-old male with early refractory hypertension, hypokalemia, serum potassium level of 3.4 mmol/l and hypoaldosteronemia was indicated in the present study. According to the results of laboratory tests and examinations, the patient was suspected of having Liddle's syndrome (LS). Genetic analysis of SCNN1B revealed a deletion mutation (c.1721delC). This mutation caused a length extension of SCNN1B coding sequence, which resulted in p.Pro574HisfsX675. A total of 34 family members were enrolled in the study and 29 of these family members underwent genetic testing. A total of 10 family members were clinically diagnosed with hypertension. Notably, 5 family members shared the same gene mutation as the proband and all cases with the mutation had hypertension. Blood pressure of the gene mutation carriers was well controlled by tailored treatment. In conclusion, a patient with early onset and refractory hypertension, hypokalemia and hypoaldosteronemia was diagnosed clinically and genetically with LS. Notably, a novel mutation (c.1721delC) was identified by DNA analysis. The present findings indicate that genetic analysis is useful, not only in the diagnosis of LS, but also in designing a tailored treatment.
Introduction
Liddle's syndrome (LS), first described by Liddle et al (1) in 1963, is characterized by high urinary potassium excretion, low urinary sodium excretion and maintained hypokalemia and volume expansion, resulting in hypertension and suppressed aldosterone excretion. Liddle hypothesized that excessive sodium reabsorption in the distal kidney tubules may be the reason for this clinical presentation. LS is a hereditary disease caused by mutations of epithelial sodium channels (ENaCs), which are located in kidney distal convoluted tubules. ENaCs are constructed by three homologous subunits. Each α-, β-, γ-ENaC subunit has a highly conserved sequence termed the PY motif (Pro-Pro-Pro-X-Tyr motif) that serves as a binding site for Nedd4-2 in the process of ENaC ubiquitylation and endocytosis (2, 3) . LS is genetically heterogeneous and arises from mutations in the cytoplasmic C-terminus of either the β or γ subunit of the amiloride-sensitive ENaC. Previous findings have indicated that mutations in the α-subunit of ENaC genes are responsible for multisystem pseudohypoaldosteronism type 1, which is a rare autosomal recessive aldosterone unresponsiveness syndrome (4) . Mutations in the β or γ subunits of ENaC genes have been reported in a previous study and were strongly associated with LS (5) . However, LS is a rare disease and can be easily overlooked or misdiagnosed. Hypertension caused by LS presents as refractory and hard to control. Inhibitors of sodium transport in the distal nephron, including amiloride and triamterene, are effective treatment options in patients with LS. Previous studies revealed that mineralocorticoid antagonists, including spironolactone, are not effective for patients with LS (6, 7) .
In the present study, a young man presented with early-onset and refractory hypertension with hypokalemia and was clinically suspected of having LS. His pedigree was surveyed and molecular genetic studies were conducted.
Materials and methods
Clinical data. A 19-year-old male was admitted with early-onset hypertension and hypokalemia in June 2012 to A family with Liddle's syndrome caused by a new c.1721 deletion mutation in the epithelial sodium channel β-subunit Genetic diagnosis. Genetic analysis was performed on the proband and his family members. DNA was extracted from peripheral blood leukocytes using a TIANamp Blood DNA kit (Tiangen Biotech Co., Ltd., Beijing, China). The reference sequences of SCNN1B and SCNN1G were obtained from GenBank (https://www.ncbi.nlm.nih. gov/genbank/accession no. NM_000336.2 for SCNN1B and NM_001039.3 for SCNN1G). Primers were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA, USA). All the exons of SCNN1B and SCNN1G were sequenced, but mutations were only identified in the last exon of SCNN1B. Polymerase chain reaction (PCR) was used to amplify the last exons of β and γ subunits of the ENaC based on the following primers: β, forward, 5'-TGC TGT CCT CAT CGA GTT TG-3' and reverse, 5'-CCT CCA CCA GCT CGG CCA CG-3'; and γ, forward, 5'-GCT TGG GTA GGA GGG AGA-3' and reverse, 5'-CCG TAA AGA GCT GCA TCA G-3'. PCR products were purified using an Agarose Gel Purification kit (Beijing Biomed Gene Technology Co., Ltd., Beijing, China). All samples were sequenced in both forward and reverse directions with an Applied Biosystems 3730/3730xl DNA Analyzers 3730 XL (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). High resolution melting (HRM) was used for detection of the mutation in other family members. Genotyping was performed using a SYTO9 fluorescent dye (Thermo Fisher Scientific, Inc.) and the HRM method on a Rotor-gene 6200 system (Qiagen, Inc., Valencia, CA, USA), according to the manufacturer's protocol. In brief, a short fragment containing the altered gene section was amplified with the forward primer 5'-TGC TGT GCC TCA TCG AGT TTG-3' and a reverse primer of 3'-CCT CCA CCA GCT CGG CCA CG-5' using 5 µM of SYTO9 fluorescent dye. Subsequently, the PCR products were genotyped using HRM analysis. DNA samples with known genotypes in the present pedigree were used as positive controls and ddH 2 O was used as a negative control.
In order to exclude single nucleotide polymorphisms induced by the gene change, HRM analysis was performed on 500 normal control DNA samples obtained from the Human Genome Research Center and College of Life Science and Technology of Huazhong University of Science and Technology (Wuhan, China).
Results
The proband had early onset hypertension with a blood pressure (BP) ranging from 140-230/80-140 mmHg. The patient was asymptomatic when his BP was <180/100 mmHg. Blood biochemistry parameters and urine tests were performed and plasma renin and aldosterone concentration, cortisol circadian rhythm, plasma catecholamine, and thyroid function were tested. Results indicated that potassium level was 3.4 mmol/l and plasma renin and aldosterone levels were normal while the subject was supine; however, these levels were suppressed while the subject was upright. Furthermore, renin and aldosterone levels decreased after the patient stood up. Detailed clinical data and positive auxiliary examination results of the proband (III-11) are presented in Table I . The results of parameters and tests not shown were all in the normal range. With the exception of BP, no abnormalities were detected on physical examination. Imaging was also normal, including imaging of the abdomen, renal artery and pituitary gland. Notably, hypertension was refractory following treatment with multiple drugs, including calcium channel blockers, angiotensin-converting-enzyme inhibitors, β-receptor blockers and diuretics. Based on the aforementioned data, LS was suggested as a potential diagnosis. A DNA sample from the patient was analyzed for detection of ENaC mutation. A novel deletion mutation (c.1721delC) was identified, which was suspected to be the cause of hypertension.
There were 34 members from three generations in the current pedigree. As indicated in Fig. 1 , 29 family members were enrolled for genetic testing and the 4 family members could not be contacted and 1 family member was deceased. The clinical data of all members in this pedigree are presented in Table II . A total of 10/29 members in this pedigree were clinically diagnosed with hypertension. III-10 (sibling of the proband) was diagnosed with hypertension at the age of 20. Without regular treatment, the BP of III-10 fluctuated between 150-160/90-110 mmHg and was poorly controlled. Furthermore, the subject's potassium level was 3.2 mmol/l. In the proband's father's family, I-2, II-1, II-3 and II-5 (the proband's father) all developed hypertension in their 40s. In the proband's mother's family, I-4 was died as a result of cerebral vascular disease in her 70s. It was unknown whether this subject had hypertension because she had never received a physical examination. II-6 (the proband's mother) also exhibited early-onset hypertension at the age of 30. Her BP was 140/90 mmHg and her potassium level was 3.5 mmol/l. The maternal aunts of the proband (II-8, II-9) had presented with high BP at the same age as II-6, but without hypokalemia. The proband's cousin (III-16, son of II-8) had not been diagnosed with hypertension, but a random BP check revealed a BP of 140/100 mmHg with a serum potassium level of 5.0 mmol/l.
DNA sequencing revealed a deletion of cytosine at nucleotide 1721 of the coding DNA structure (c.1721delC) compared with the wild-type sequence in SCNN1B in the proband III-11, as indicated in Fig. 2 . This deletion can cause a length extension of the SCNN1B coding sequence from 1,923 to 2,025 bp, leading to the modification of the open reading frame after the proline at position 574 and introduction of a new stop codon at position 675 (p.Pro574HisfsX675). Family members III-10, III-16, II-6, II-8, and II-9 shared the same mutation. However, no 1721delC mutation was found in the other family members. No mutation of SCNN1G coding sequences was detected in the proband. The deletion mutation was identified in 6 people in the pedigree.
The HRM curve was compared between patients with and without c.1721delC mutation in the pedigree. The bimodal HRM curves of II-6, II-8, II-9 and III-10, who were discovered to be mutation carriers, are presented in Fig. 3 . All other individuals involved in the study produced a unimodal curve.
Notably, HRM curves of III-11 and III-16 were not observed due to technical failure of extracting DNA. Furthermore, HRM analysis was performed on 500 normal control DNA samples. Smooth unimodal curves were shown in accordance with non-mutation carriers in this family.
Irbesar tan, hydrochlorothiazide, spironolactone, amlodipine, bisoprolol and nifedipine treatment were all prescribed before LS was diagnosed; however, the proband's BP remained poorly controlled. After genetic testing, treatment was switched to amiloride and low-sodium diet (2 g NaCl/day). BP was gradually decreased to 110/80 mmHg and potassium level increased to 4.4 mmol/l after 4 weeks of treatment. The proband was followed up with phone calls and re-evaluated after amiloride treatment for 3 years. BP was successfully controlled at the 3-year follow up. The patient's left ventricular hypertrophy (LVH), fundus artery and kidney function was improved at his second evaluation, as indicated in Table III . Notably, family members II-6, II-8, II-9 and III-10 also had their BP controlled by amiloride therapy.
Comparison of the proband's clinical data and auxiliary examination results before and after amiloride treatment for 3 years revealed an improvement in the proband's condition: High BP was decreased to a normal range, serum potassium was increased, and LVH and fundus conditions were improved. Brief clinical history and blood biochemical parameters of 29 individuals in this family are shown in the table above. BP was measured on two different days. Among the family members, 10/29 were clinically diagnosed with HTN and 5 of them shared the same gene mutation with III-11. All gene mutation carriers had early onset hypertension with onset age from 20-30 years old. Mutation carriers III-10 and III-11 had hypokalemia, while the remaining five carriers had normal serum potassium. HTN, hypertension; BP, blood pressure; UK, unknown; Na, serum sodium; K, serum potassium; CVD, cerebrovascular disease; T2DM, type 2 diabetes.
Discussion
In 1994, LS was confirmed by the discovery of a molecular defect that was an activating mutation in the subunit of ENaC (8) . Numerous mutations in ENaC have now been reported (Table IV) . The majority of these were missense mutations, but deletion and insertion mutations have also been reported. Regardless of the mutation in SCNN1B and Comparison of HRM analysis between patients with mutation carriers and normal controls. The bimodal HRM curves of II-6, II-8, II-9 and III-10, patients who were discovered to be mutation carriers, are indicated. All other individuals involved in this study produced a unimodal curve. HRM analysis was also performed on 500 normal control DNA samples. Smooth unimodal curves were observed in accordance with non-mutation carriers in this family. HRM, high resolution melting. Comparison of the proband's clinical data and auxiliary examination results before and after amiloride treatment for 3 years. The results indicate improvement of the proband's condition: High BP decreased to normal range, serum potassium increased, and there was improvement in LV and IVS hypertrophy, as well as to organ damage in the kidney and fundus. BP, blood pressure; LV, left ventricular; LVID, LV internal diameter; LVEDV, LV end diastolic volume; IVS, interventricular septum; PWT, posterior wall thickness.
SCNN1G, a frameshift mutation may cause the LS phenotype. Genetic defects frequently affect a highly conserved sequence known as the PY motif (starting from p.616 in SCNN1B and p.623 in SCNN1G), which serves as a binding site for Nedd4-2. Nedd4-2 acts as a bridge that connects the PY motif of the ENaC at one side and combines with ubiquitin ligase on the other side. Notably, ubiquitylation is important for degradation of the ENaC to maintain a constant number of ENaCs. In the process of ENaC ubiquitylation and endocytosis, the mutated PY motif fails to bind with Nedd4-2, resulting in an excessive number and overactivation of ENaCs on the cell surface, which leads to an increase of sodium and fluid absorption in the distal convoluted tubules (29) .
The proband in the current case was characterized by early-onset refractory hypertension with features of familial aggregation. For this patient, signs of primary aldosteronism (PA) were looked for based on his hypertension and hypokalemia, but no mass was found in the adrenal gland. The Endocrinology Society guidelines recommend the use of aldosterone-to-renin ratio as the most reliable test for detecting PA (30) . Notably, the levels of renin in the current patient were very low without hyperaldosteronemia and serum aldosterone was low. For the present case there were several other possibilities, including congenital adrenal hyperplasia (CAH), apparent mineralocorticoid excess (AME), LS and renal tubular acidosis (RTA) (31) . CAH is a group of d Term used to describe mutation in source article. fs, frameshift; HT, hypertension; R↓, low plasma renin activity; A↓, low plasma aldosterone; K↓, low plasma K+ levels; SD, sudden death. autosomal recessive disorders encompassing enzyme deficiencies in the adrenal steroidogenesis pathway, which lead to impaired cortisol biosynthesis. A lack of 17α-hydroxylase and 21-hydroxylase is the most common type of CAH, which can lead to notable sex character changes, including masculinization, precocious puberty and testicular tumors (32, 33) . AME is a syndrome associated with the absence or impaired activity of the enzyme 11β-hydroxysteroid dehydrogenase (34) . Diagnosis relies on a triad of hypertension, hypokalemia and suppressed plasma aldosterone levels, plus an abnormal urinary cortisol to cortisone ratio and electrolyte disturbance (34) . It is difficult to differentiate from LS in certain cases. However, AME patients are normally sensitive to spironolactone treatment. Furthermore, certain RTA patients can present with hypertension and hypokalemia, but their symptoms are often accompanied with other features, including dehydration, obtundation, restricted skeletal growth and urinary tract stones. Such cases are usually detected in infancy. However, milder versions of the disease typically present later in childhood (35) . All of the clinical features and auxiliary examination results in the present case indicated the possibility of LS. The genetic diagnosis for LS is an indispensable method alongside typical clinical presentation. Genetic analysis of the current case indicated a mutated β ENaC subunit, c.1721delC, which was located before the PY coding sequence, and caused a length extension of SCNN1B coding sequence from 1,923 to 2,025 bp. This may affect the combination of Nedd4-2 and the ubiquitylation of ENaC. This mutation was also detected in 5 other family members who presented with hypertension in early adulthood. A notable finding of the present study was that hypokalemia was only present in the proband's immediate family, but not in other mutation carriers. This result indicated that differences of penetrance are possible, even in the same pedigree and among carriers of the same mutation. Furthermore, the present results revealed that the mutation had an autosomal dominant inheritance pattern and presented with features of pedigree co-segregation.
Treatment for LS includes a sodium-restricted diet, inhibition of ENaCs and potassium supplementation. Amiloride is a typical ENaC inhibitor, which combines with ENaCs before the PY motif site to block the ENaC. By inhibiting Na + -K + exchange and Na + -H + exchange, amiloride can alleviate sodium and water retention to further improve hypertension and hypokalemia. In the current case, the patient had poorly controlled BP with a range of 140-220/80-140 mmHg and had developed gingival hyperplasia subsequent to high doses of nifedipine. However, after single amiloride treatment for 3 years, BP was well controlled and end-organ damage had been reversed. The antihypertensive benefit of amiloride for LS was also verified in other family members who carried the same mutation, providing further supporting evidence for the diagnosis of LS.
In conclusion, a patient with LS was diagnosed clinically and genetically in the present study. The patient's clinical presentation included early onset and refractory hypertension, familial aggregation, hypokalemia and hypoaldosteronemia. To the best of our knowledge, the deletion mutation (c.1721delC) has not been reported in previous literature. The present findings indicated that genetic analysis is helpful in the diagnosis of hypertension in a patient who is clinically suspected of LS. Furthermore, the results suggested that it is also useful to screen the proband's family members. These findings demonstrate the benefits of genetic testing and tailored treatment.
